Soligenix, Inc. (SNGX) is a late-stage biopharmaceutical company committed to designing and developing transformational products to treat rare diseases where there is an unmet medical need. With a highly diverse portfolio of candidates, Soligenix is mainly focused on complex biotherapeutic products for life-threatening conditions like cutaneous t-cell lymphoma, oral mucositis, cancer, GI disorders, and various types of vaccines.
Based in Princeton, New Jersey, USA, Soligenix works with an unwavering commitment to accelerating the development of new treatments for unmet medical needs. To ensure maximum efficacy and safety in their products, they employ a cutting-edge technology and science-based approach.
Soligenix operates through two business segments: BioTherapeutics and Vaccines/BioDefense. The BioTherapeutics segment focuses on the development of a novel photodynamic therapy using synthetic hypericin, a compound activated by safe, visible light for the treatment of cutaneous T-cell lymphoma (CTCL), a type of non-Hodgkin's lymphoma. This segment also focuses on the development of other rare disease drug candidates. The Vaccines/BioDefense segment includes researches on vaccines and therapeutics for military and civilian applications, primarily addressing emerging and antibiotic-resistant infectious diseases.
The company's leading BioTherapeutics product candidates are based on first-in-class photodynamic therapy utilizing safe visible light activation. This technology with synthetic hypericin has demonstrated compelling response rates in Phase 2 clinical trials when activated with safe visible light at the time of treatment.
The Vaccines/BioDefense business segment is very significant due to the increasing threats from bio-terrorism and emerging infectious diseases. This division is highly adept at developing medical countermeasures needed to protect against these threat agents.
Despite being relatively small in size, Soligenix's impact and potential in the biotech sphere are considerable. Its approach of focusing on rare diseases that lack sufficient treatment methods reflects an important commitment to addressing the unmet medical needs of patients globally. Thus, Soligenix, Inc. (SNGX) is dedicated to bringing new hope to patients by developing promising new therapies for diseases that do not yet have effective treatments.